Trial Profile
A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Tabelecleucel (Primary)
- Indications B-cell lymphoma; Carcinoma; Diffuse large B cell lymphoma; Haemophagocytic lymphohistiocytosis; Hodgkin's disease; Leiomyosarcoma; Lymphoproliferative disorders; Nasopharyngeal cancer; Non-Hodgkin's lymphoma; Post-transplant lymphoproliferative disorder
- Focus Registrational; Therapeutic Use
- Sponsors Atara Biotherapeutics
- 29 Nov 2023 Results presented in an Atara Biotherapeutics media release.
- 29 Nov 2023 According to an Atara Biotherapeutics media release, pooled analysis of four single-arm, open-label studies, (NCT04554914, NCT00002663, NCT01498484 and multicenter, expanded-access protocol NCT02822495) (n=18), will be presented as an oral session at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Annual Congress, 2023.
- 13 Dec 2022 Results evaluating efficacy and safety of Tabelecleucel presented at the 64th American Society of Hematology Annual Meeting and Exposition